RXRX Recursion Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RXRX

Price (delayed)

$2.96

Market cap

$1.57B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.16

Enterprise value

$980.91M

?
Relative Growth: Rel. Growth: 57
Relative Strength: Rel. Strength: 12
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 8

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients ...

Highlights
The gross margin has grown by 44% since the previous quarter and by 11% year-on-year
The company's EPS rose by 36% YoY and by 19% QoQ
RXRX's revenue is down by 11% since the previous quarter but it is up by 11% year-on-year
RXRX's equity is up by 10% year-on-year but it is down by 9% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.recursionpharma.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RXRX

RXRX stock price

How has the Recursion Pharmaceuticals stock price performed over time
Intraday
-1.66%
1 week
0.51%
1 month
-8.36%
1 year
-52.72%
YTD
-27.63%
QTD
-19.35%

Financial performance

How have Recursion Pharmaceuticals's revenue and profit performed over time
Revenue
$66.41M
Gross profit
$4.8M
Operating income
-$585.27M
Net income
-$559.78M
Gross margin
7.2%
Net margin
-842.9%
The gross margin has grown by 44% since the previous quarter and by 11% year-on-year
Recursion Pharmaceuticals's gross profit has increased by 29% from the previous quarter and by 23% YoY
Recursion Pharmaceuticals's net income has increased by 13% from the previous quarter and by 2.6% YoY
The net margin is up by 12% year-on-year and by 2.4% since the previous quarter

Price vs fundamentals

How does RXRX's price correlate with its fundamentals

Growth

What is Recursion Pharmaceuticals's growth rate over time

Valuation

What is Recursion Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.52
P/S
23.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.77
The company's EPS rose by 36% YoY and by 19% QoQ
RXRX's price to book (P/B) is 55% lower than its 5-year quarterly average of 3.4 and 20% lower than its last 4 quarters average of 1.9
RXRX's equity is up by 10% year-on-year but it is down by 9% since the previous quarter
RXRX's price to sales (P/S) is 66% lower than its 5-year quarterly average of 68.9 and 28% lower than its last 4 quarters average of 32.9
RXRX's revenue is down by 11% since the previous quarter but it is up by 11% year-on-year

Efficiency

How efficient is Recursion Pharmaceuticals business performance
RXRX's ROIC is down by 29% YoY
Recursion Pharmaceuticals's return on equity has increased by 27% YoY and by 15% QoQ
Recursion Pharmaceuticals's return on assets has increased by 25% YoY and by 14% QoQ
The company's return on sales rose by 12% YoY

Dividends

What is RXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RXRX.

Financial health

How did Recursion Pharmaceuticals financials performed over time
The quick ratio has grown by 34% year-on-year
The company's current ratio rose by 33% YoY
The debt is 93% smaller than the equity
RXRX's debt to equity is down by 30% year-on-year
The debt has declined by 22% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.